Medacist Announces Commercial Release of RxAuditor Investigate – The First Offering of the Genesis Analytics Platform
CHESHIRE, CT, October 9, 2019 – David J. Brzozowski, Sr, President & CEO, today announced the commercial release of RxAuditor Investigate.
“I am proud to announce that Medacist Solutions Group commercially released RxAuditor Investigate on October 1, 2019.
The innovation of RxAuditor Investigate was born from the need to curate list of “at-risk” individuals from a larger list of statistically identified diversion outliers.
The previous need to perform time-consuming manual audits is eliminated by the incorporation of autonomous diversion auditing by evaluation, scoring, and ranking of risk – thus reducing false positives and curating a targeted list of “at-risk” individuals.
RxAuditor Investigate’s main objective is to target risk within the medication-use-process and identify areas of risk across your organization at any level of responsibility – with a single glance.
Key features include:
- Target individual outliers by risk score across your enterprise
- Evaluate diversion incidents enterprise wide based on level of risk
- Document evidence in support of each team member’s evaluation of outliers’ activity
- Collaborate with team members using a workflow management portal
- Decide collectively with members of the drug diversion team
As the innovative leader in drug diversion analytics for the healthcare industry, we do not rest on our laurels. The Medacist Development Team is always looking to improve the overall customer experience and will work diligently to advance the algorithmic processes to deliver the highest level of diversion intelligence in the industry to ensure accurate, comprehensive, and innovative drug diversion analytics for your organization.
Thank you for your business, your trust, and your confidence. It is our pleasure to work with you and your team, and we can’t wait to share our latest innovation, RxAuditor Investigate, with you!”
Please download the entire press release below.